Inventor
FRUEH KLAUS
US19 patents
⚠️ This page may combine multiple inventors who share the name “FRUEH KLAUS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV OREGON HEALTH & SCIENCE
14 patentsUS9249427B2Feb 2, 2016
Recombinant HCMV and RHCMV vectors and uses thereof
UNIV OREGON HEALTH & SCIENCE24 citations91
US10101329B2Oct 16, 2018
CMV glycoproteins and recombinant vectors
UNIV OREGON HEALTH & SCIENCE9 citations83
US10428118B2Oct 1, 2019
Human cytomegalovirus comprising exogenous antigens
UNIV OREGON HEALTH & SCIENCE5 citations82
US9783823B2Oct 10, 2017
Cytomegalovirus vectors enabling control of T cell targeting
UNIV OREGON HEALTH & SCIENCE14 citations82
US9982241B2May 29, 2018
Recombinant HCMV and RHCMV vectors and uses thereof
UNIV OREGON HEALTH & SCIENCE13 citations81
US10688164B2Jun 23, 2020
CMV vectors comprising microRNA recognition elements
UNIV OREGON HEALTH & SCIENCE8 citations80
US10532099B2Jan 14, 2020
Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
UNIV OREGON HEALTH & SCIENCE8 citations80
US9541553B2Jan 10, 2017
CMV glycoproteins and recombinant vectors
UNIV OREGON HEALTH & SCIENCE10 citations79
US10995121B2May 4, 2021
Human cytomegalovirus comprising exogenous antigens
UNIV OREGON HEALTH & SCIENCE1 citations71
US10316334B2Jun 11, 2019
Cytomegalovirus vectors enabling control of T cell targeting
UNIV OREGON HEALTH & SCIENCE4 citations71
US11692012B2Jul 4, 2023
Human cytomegalovirus comprising exogenous antigens
UNIV OREGON HEALTH & SCIENCE0 citations60
US11305015B2Apr 19, 2022
Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
UNIV OREGON HEALTH & SCIENCE0 citations59
US11266732B2Mar 8, 2022
Recombinant HCMV and RHCMV vectors and uses thereof
UNIV OREGON HEALTH & SCIENCE0 citations59
US11091779B2Aug 17, 2021
Methods and compositions useful in generating non canonical CD8+ T cell responses
UNIV OREGON HEALTH & SCIENCE1 citations59
VIR BIOTECHNOLOGY INC
3 patentsUS10894078B2Jan 19, 2021
HIV vaccines comprising one or more population episensus antigens
VIR BIOTECHNOLOGY INC4 citations81
US11628215B2Apr 18, 2023
HIV vaccines comprising one or more population episensus antigens
VIR BIOTECHNOLOGY INC0 citations59
US11554168B2Jan 17, 2023
HIV vaccines comprising one or more population episensus antigens
VIR BIOTECHNOLOGY INC0 citations59